MX2018010586A - Nanovacuna de activacion de "sting" para inmunoterapia. - Google Patents
Nanovacuna de activacion de "sting" para inmunoterapia.Info
- Publication number
- MX2018010586A MX2018010586A MX2018010586A MX2018010586A MX2018010586A MX 2018010586 A MX2018010586 A MX 2018010586A MX 2018010586 A MX2018010586 A MX 2018010586A MX 2018010586 A MX2018010586 A MX 2018010586A MX 2018010586 A MX2018010586 A MX 2018010586A
- Authority
- MX
- Mexico
- Prior art keywords
- nanovacuna
- immunotherapy
- diblock copolymer
- compositions
- sting activation
- Prior art date
Links
- 230000004913 activation Effects 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 229920000359 diblock copolymer Polymers 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302637P | 2016-03-02 | 2016-03-02 | |
| PCT/US2017/020451 WO2017151922A1 (en) | 2016-03-02 | 2017-03-02 | Sting activating nanovaccine for immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018010586A true MX2018010586A (es) | 2019-03-28 |
Family
ID=59743242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010586A MX2018010586A (es) | 2016-03-02 | 2017-03-02 | Nanovacuna de activacion de "sting" para inmunoterapia. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11376324B2 (enExample) |
| EP (1) | EP3423044A4 (enExample) |
| JP (1) | JP2019511483A (enExample) |
| KR (1) | KR20180114946A (enExample) |
| CN (1) | CN109069440A (enExample) |
| AU (1) | AU2017225769B2 (enExample) |
| CA (1) | CA3016457A1 (enExample) |
| MX (1) | MX2018010586A (enExample) |
| WO (1) | WO2017151922A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL280430B2 (en) | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| CA3029644A1 (en) | 2016-07-06 | 2018-01-11 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES |
| WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| CN111556760A (zh) * | 2017-11-06 | 2020-08-18 | 纪念斯隆-凯特林癌症中心 | 作为疫苗免疫佐剂的热灭活的牛痘病毒 |
| CN111727054A (zh) * | 2018-01-04 | 2020-09-29 | 中央研究院 | 用于增加疗效的可与细胞结合的免疫佐剂 |
| JP7542257B2 (ja) * | 2018-01-25 | 2024-08-30 | エイシーエム バイオラブズ プライベート リミテッド | 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法 |
| EP3743103A4 (en) * | 2018-01-26 | 2021-03-17 | The Regents of The University of California | INTRANASAL ADMINISTRATION OF CYCLIC DI-NUCLEOTIDE ADJUVED VACCINE FOR TUBERCULOSIS |
| EP3802534B1 (en) | 2018-05-25 | 2022-07-13 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| WO2020014127A1 (en) | 2018-07-10 | 2020-01-16 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| WO2020028565A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Tricyclic heteraryl compounds as sting activators |
| CN109453364B (zh) * | 2018-09-30 | 2021-10-15 | 郑州大学第一附属医院 | 一种双重响应性纳米颗粒及其在肿瘤抑制中的应用 |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| WO2020146237A1 (en) | 2019-01-07 | 2020-07-16 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| WO2020178769A1 (en) * | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| BR112021023940A2 (pt) * | 2019-05-28 | 2022-02-15 | Univ Texas | Composições responsivas ao ph e usos das mesmas |
| KR20220024565A (ko) | 2019-06-22 | 2022-03-03 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 생분해성 초-pH 민감성 중합체 |
| BR112022008849A2 (pt) * | 2019-11-07 | 2022-08-23 | Samyang Holdings Corp | Composição para induzir imunidade a um ingrediente ativo, e, método para preparar uma composição para induzir imunidade a um ingrediente ativo |
| AU2020387279B2 (en) * | 2019-11-18 | 2026-04-09 | Onconano Medicine, Inc. | pH responsive compositions, formulations, and methods of imaging a tumor |
| GB201918963D0 (en) * | 2019-12-20 | 2020-02-05 | Provost Fellows Scholars And Other Members Of Board Of Trinity College Dublin | Polymeric nanoparticles as vaccine adjuvants |
| CN111184738B (zh) * | 2020-03-04 | 2021-05-28 | 北京大学 | 一种二嵌段共聚物或其药学上可接受的盐在制备抗病毒药物中的应用、药物组合物 |
| CN113577255B (zh) * | 2020-04-30 | 2023-09-08 | 中国科学院上海药物研究所 | 肿瘤纳米疫苗、其制备方法及用途 |
| MX2023002797A (es) * | 2020-09-08 | 2023-05-04 | Univ Texas | Composiciones activadoras de sting polivalente y usos de las mismas. |
| EP4240781A4 (en) * | 2020-11-03 | 2026-02-18 | Onconano Medicine Inc | pH-sensitive therapeutic compositions |
| EP4066824A1 (en) * | 2021-03-31 | 2022-10-05 | Dompe' Farmaceutici S.P.A. | Combination therapy for covid-19 vaccination |
| US20250127921A1 (en) * | 2021-08-10 | 2025-04-24 | Wisconsin Alumni Research Foundation | Ph-responsive nano particle for delivery of ribonucleoproteins |
| WO2023142341A1 (zh) * | 2022-01-26 | 2023-08-03 | 深圳湾实验室坪山生物医药研发转化中心 | 肿瘤免疫治疗 |
| CN114456331A (zh) * | 2022-02-16 | 2022-05-10 | 北京大学 | 能够与膜结合的聚合物及其制备方法和用途 |
| WO2024226815A2 (en) * | 2023-04-28 | 2024-10-31 | University Of Washington | B-cell epitopes of treponema pallidum antigens for use in a syphilis vaccine |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4520019A (en) | 1982-04-29 | 1985-05-28 | Ribi Immunochem Research, Inc. | Stable composition and preparation thereof |
| US4579945A (en) | 1982-04-29 | 1986-04-01 | Ribi Immunochem Research, Inc. | Purification of trehalose dimycolates |
| US4505899A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4435386A (en) | 1982-05-26 | 1984-03-06 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4436728A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4505900A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US5416070A (en) | 1988-07-08 | 1995-05-16 | Immunotherapeutics, Inc. | Composition for macrophage activation |
| US4950645A (en) | 1988-07-08 | 1990-08-21 | Immunotherapeutics, Inc. | Composition for macrophage activation |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US5980912A (en) | 1997-03-25 | 1999-11-09 | Zonagen, Inc. | Chitosan induced immunopotentiation |
| IT1306129B1 (it) | 1999-04-13 | 2001-05-30 | Sigma Tau Ind Farmaceuti | Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti |
| EP1326865B1 (en) | 2000-10-12 | 2009-05-06 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| CN1370601A (zh) * | 2001-02-22 | 2002-09-25 | 中国科学院成都有机化学研究所 | 单剂基因工程乙肝疫苗缓释微球的制备方法 |
| US20050175625A1 (en) * | 2002-07-12 | 2005-08-11 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| US9200036B2 (en) * | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| ES2259914B1 (es) * | 2005-03-14 | 2007-06-16 | Advanced In Vitro Cell Technologies, S.L. | Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas. |
| JP2008540558A (ja) * | 2005-05-10 | 2008-11-20 | エモリー・ユニバーシティ | ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略 |
| EP2139513B1 (en) * | 2007-03-28 | 2012-09-05 | National Institute of Immunology | Polymer particles based vaccine |
| WO2008148057A2 (en) * | 2007-05-23 | 2008-12-04 | Vical Incorporated | Cationic lipids compositions and methods for enhancing immune responses to vaccines |
| US9532956B2 (en) * | 2009-04-18 | 2017-01-03 | Massachusetts Institute Of Technology | PH sensitive biodegradable polymeric particles for drug delivery |
| WO2010138193A2 (en) * | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| WO2012039741A1 (en) * | 2010-09-22 | 2012-03-29 | The Board Of Regents Of The University Of Texas System | Novel block copolymer and micelle compositions and methods of use thereof |
| US20140308363A1 (en) * | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| US9511152B2 (en) * | 2012-04-05 | 2016-12-06 | The Board Of Regents Of The University Of Texas System | Multicolored pH-activatable fluorescence nanoplatform |
| SG11201502796RA (en) * | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| CN106573076A (zh) * | 2014-06-06 | 2017-04-19 | 德克萨斯大学系统董事会 | pH响应聚合物库及其纳米探针 |
| KR102764250B1 (ko) * | 2015-09-14 | 2025-02-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 지질양이온성 덴드리머 및 이의 용도 |
| CN105214097A (zh) * | 2015-10-30 | 2016-01-06 | 中国科学院福建物质结构研究所 | 一种口服纳米疫苗运载体的免疫实施与检测技术 |
| US11096899B2 (en) * | 2018-09-07 | 2021-08-24 | Wisconsin Alumni Research Foundation | Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment |
-
2017
- 2017-03-02 CN CN201780027045.XA patent/CN109069440A/zh active Pending
- 2017-03-02 KR KR1020187027939A patent/KR20180114946A/ko not_active Ceased
- 2017-03-02 US US16/081,911 patent/US11376324B2/en active Active
- 2017-03-02 AU AU2017225769A patent/AU2017225769B2/en active Active
- 2017-03-02 CA CA3016457A patent/CA3016457A1/en active Pending
- 2017-03-02 MX MX2018010586A patent/MX2018010586A/es unknown
- 2017-03-02 JP JP2018545910A patent/JP2019511483A/ja active Pending
- 2017-03-02 EP EP17760821.3A patent/EP3423044A4/en active Pending
- 2017-03-02 WO PCT/US2017/020451 patent/WO2017151922A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017225769A1 (en) | 2018-09-20 |
| WO2017151922A1 (en) | 2017-09-08 |
| JP2019511483A (ja) | 2019-04-25 |
| KR20180114946A (ko) | 2018-10-19 |
| AU2017225769B2 (en) | 2023-01-05 |
| EP3423044A4 (en) | 2019-11-20 |
| EP3423044A1 (en) | 2019-01-09 |
| CN109069440A (zh) | 2018-12-21 |
| CA3016457A1 (en) | 2017-09-08 |
| US20190060446A1 (en) | 2019-02-28 |
| US11376324B2 (en) | 2022-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003636A1 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson. | |
| AR100215A1 (es) | Conjugados de anticuerpo-fármaco anti-ptk7 | |
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| GEAP202115055A (en) | Anti-cd27 antibodies | |
| EP4523756A3 (en) | Immunotherapeutic vaccine and antibody combination therapy | |
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| MX388743B (es) | Conjugados oligonucleótido-péptido. | |
| MX2017008186A (es) | Anticuerpos humanos para la hemaglutinina de influenza. | |
| CY1122549T1 (el) | Παραγωγα καρβαζολης | |
| EA201800148A1 (ru) | Оспенная вакцина для лечения рака | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| CL2016002794A1 (es) | Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
| MX2023001540A (es) | Vacunas contra el cancer y metodos de tratamiento que las utilizan. | |
| NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| EA202191145A1 (ru) | Вакцина виб 4/91 с гетерологичным шиповидным белком | |
| WO2015054678A3 (en) | Human papilloma virus therapeutic vaccine | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| EA201892003A1 (ru) | Лечение атопического дерматита собак | |
| MX2017015004A (es) | Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina. | |
| MX381745B (es) | Vacunas de pestivirus para temblores congenitos. | |
| AR104271A1 (es) | Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante |